Category - News

Developments

Keystone Dental Holdings to combine with Check-Cap

Closely-held Keystone Dental Holdings agreed to a definitive business combination with Check-Cap (NASDAQ:CHEK), with stockholders of Keystone becoming majority holders of the combined company. If completed, the business...

August 17, 2023

Developments

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Eyenovia (NASDAQ:EYEN) entered an agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) to acquire the exclusive U.S. rights to distribute and sell Formosa’s APP13007 (clobetasol propionate ophthalmic...

August 16, 2023

Markets

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Leerink Partners raised its price target for Centessa Pharmaceuticals (NASDAQ:CNTA) to $11 from $6, and reiterated an “outperform” rating, citing an improved outlook for its pipeline. The stock closed at $6.62 on Aug...

August 15, 2023

Markets

Leerink starts Turnstone Biologics at MP; PT $13

Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...

August 15, 2023

Developments

FDA clears Revance’s DAXXIFY injection for cervical dystonia

The FDA approved the first therapeutic indication for Revance Therapeutics’ (NASDAQ:RVNC) DAXXIFY for injection for the treatment of cervical dystonia in adults. Cervical dystonia is a chronic, debilitating disease in...

August 14, 2023

Developments

Anixa to present ovarian cancer CAR-T therapy at CAR-TCR Summit

Dr. Pamela Garzone, chief development officer of Anixa Biosciences (NASDAQ:ANIX) will present, “Developing a CAR-T for Ovarian Cancer and Other Solid Tumors,” at the 8th Annual CAR-TCR Summit in Boston...

August 14, 2023

Developments

Plus Therapeutics posts positive Phase 1 data in leptomeningeal metastases

Plus Therapeutics (NASDAQ:PSTV) reported positive data from the ReSPECT-LM clinical study evaluating the company’s lead radiotherapeutic, rhenium (Re-186) obisbemeda, for the treatment of leptomeningeal metastases (LM)...

August 11, 2023

Developments

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

IntelGenx (TSX:IGX; OTCQB:IGXT) expects to generate $9-million in revenue over three years from an agreement for packaging a pharmaceutical oral film product that an undisclosed contract development and manufacturing...

August 11, 2023

Markets

Ladenburg cuts Salarius to neutral; removes PT

Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...

August 11, 2023

Developments

Inversago Pharma accepts $1.1-billion offer from Novo Nordisk

Closely-held Inversago Pharma of Montreal agreed to be acquired by Denmark’s Novo Nordisk for up to $1.1-billion (U.S.) in cash if certain development and commercial milestones are achieved. Inversago Pharma is a...

August 10, 2023

Category - News

Subscribe